Simcere’s Sanbexin Sublingual Tablets Added to China’s 2026 Reimbursement ListTip Ranks·Nov 15, 2026 at 11:13 PM02096+0.19%
HUTCHMED Announces Expanded Coverage on National Reimbursement Drug List for ELUNATE® and ORPATHYS® | HCM Stock NewsStockTitan·Nov 15, 2026 at 08:00 PMHCM+0.34%HAWG-0.44%
Ascentage Pharma Announces Inclusion of Lisaftoclax in China's 2026 National Reimbursement Drug List and Successful Renewal of Coverage for Olverembatinib | AAPG Stock NewsStockTitan·Nov 15, 2026 at 03:30 PMAAPG-2.66%
Sunshine Lake Pharma’s Olorigliflozin Added to China’s 2026 Reimbursement ListTip Ranks·Nov 15, 2026 at 10:38 AM06887-0.71%
Hansoh Adds Three Innovative-Medicine Indications to 2026 NRDLTip Ranks·Nov 15, 2026 at 10:38 AM03692-1.92%
Discovering Undiscovered Gems in Global for April 2026Simplywall·Apr 13, 2026 at 10:02 AM688610-4.47%002950+0.25%
"Performance" Novartis' net profit fell 15% last quarter, expects core operating profit to decline for the first time in six years this yearAASTOCKS·Feb 4, 2026 at 07:29 AMNVS+0.16%002349-1.02%
JINGHUA PHARM released its performance for the first three quarters, with a net profit attributable to the parent company of 176 million yuan, a year-on-year increase of 7.39%Zhitong·Oct 29, 2025 at 12:29 PM002349-1.02%
JINGHUA PHARM: The company's medical sodium alginate wound dressing has obtained a medical device registration certificateZhitong·Sep 18, 2025 at 07:54 AM002349-1.02%
JINGHUA PHARM's subsidiary LuHuaSenXuan leads the formulation of an industry standard approved by the National Standardization AdministrationZhitong·Sep 16, 2025 at 08:53 AM002349-1.02%
JINGHUA PHARM: Net profit of 131 million yuan in the first half of 2025, a year-on-year decrease of 3.54%Zhitong·Aug 29, 2025 at 01:18 PM002349-1.02%
JINGHUA PHARM: Ritonavir has received approval for the listing application of chemical raw materialsZhitong·Jul 23, 2025 at 08:51 AM002349-1.02%
Chinese medicine stocks opened higher, with TIBET AIM PHARM and ZHONGSHENGYAOYE both hitting the daily limit, followed by gains in JINGHUA PHARM, WOHUA PHARMACEUTICAL, TUS-PHARMA, and KANGHUI PHARMACEUTICALWallstreetcn·Jun 9, 2025 at 01:32 AM002317-2.57%002349-1.02%
JINGHUA PHARM released its first-quarter performance, with a net profit attributable to the parent company of 62.2197 million yuan, a decrease of 12.47%Zhitong·Apr 29, 2025 at 10:39 AM002349-1.02%
JINGHUA PHARM released its 2024 annual performance, with a net profit attributable to the parent company of 213 million yuan, a year-on-year decrease of 14.15%Zhitong·Apr 14, 2025 at 12:40 PM002349-1.02%